Suomen Terveystalo Oy
- Address
- Vainonkatu 9, 40100 Jyväskylä, Finland
Diseases [C] - Immune System Diseases [C20]
At Suomen Terveystalo Oy in Jyväskylä, clinical research in immune system diseases focuses on allergic and vaccine-related conditions, with studies aimed at easing symptoms and strengthening immune protection.
- Birch pollen-induced allergic rhinoconjunctivitis in children and adolescents
- Meningococcal infection prevention in healthy infants and toddlers
- Evaluation of new approaches to reduce allergy symptoms and improve vaccine-induced immune responses
These trials are designed to test a new allergy therapy and compare meningococcal vaccine responses with established options.
Diseases [C] - Cardiovascular Diseases [C14]
Cardiovascular research at this site includes studies in high-risk heart disease and heart failure, reflecting a strong focus on improving outcomes for people with serious cardiometabolic conditions.
- Adults at high risk of cardiovascular events without prior heart attack or stroke
- Heart failure with preserved or mildly reduced ejection fraction combined with obesity
- Assessment of therapies intended to lower the risk of major cardiovascular events and reduce heart failure complications
The studies are evaluating whether newer treatments can better prevent coronary events and improve quality of care in patients with advanced cardiovascular disease.
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Clinical trials in nutritional and metabolic diseases at Suomen Terveystalo Oy center on type 2 diabetes and obesity-related health problems, with an emphasis on better blood sugar control and broader metabolic benefits.
- Type 2 diabetes with inadequate glycaemic control
- People treated with metformin with or without an SGLT2 inhibitor
- Testing whether a new treatment can improve HbA1c and support weight management
This research is aimed at comparing emerging therapies with existing options to improve diabetes management in everyday practice.
Diseases [C] - Virus Diseases [C02]
Within virus diseases, the site is involved in studies of influenza prevention, with a particular interest in how well vaccination works in older adults.
- Influenza immunisation in adults aged 60 years and older
- Evaluation of high-dose influenza vaccine responses
- Testing whether a candidate vaccine can produce a stronger antibody response than an established comparator
These trials are focused on improving flu vaccine protection in a population that is more vulnerable to severe illness.
Diseases [C] - Bacterial Infections and Mycoses [C01]
Research in bacterial infections and mycoses at this Finnish clinical trial site includes vaccine studies aimed at preventing invasive bacterial disease, especially in young children.
- Meningococcal vaccination in infants and toddlers
- Comparison of immune responses to different conjugate vaccines
- Work focused on strengthening protection against serious bacterial infection
The purpose of this research is to assess whether newer vaccine options can deliver reliable immunogenicity and support better disease prevention.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Suomen Terveystalo Oy
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Cagrilintide and Semaglutide in Participants with Type 2 Diabetes Inadequately Controlled on Metformin with or without SGLT2 Inhibitors | Novo Nordisk A/S | Phase III | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cagrilintide | 1 | Unknown | 2023-11-07 | 2023-11-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.